These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33641193)

  • 1. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.
    Doña I; Torres MJ
    Allergy; 2021 Jun; 76(6):1619-1620. PubMed ID: 33641193
    [No Abstract]   [Full Text] [Related]  

  • 2. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
    Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
    Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
    Riedl MA; Aygören-Pürsün E; Baker J; Farkas H; Anderson J; Bernstein JA; Bouillet L; Busse P; Manning M; Magerl M; Gompels M; Huissoon AP; Longhurst H; Lumry W; Ritchie B; Shapiro R; Soteres D; Banerji A; Cancian M; Johnston DT; Craig TJ; Launay D; Li HH; Liebhaber M; Nickel T; Offenberger J; Rae W; Schrijvers R; Triggiani M; Wedner HJ; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan WP; Maurer M
    Allergy; 2018 Sep; 73(9):1871-1880. PubMed ID: 29688579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.
    Aygören-Pürsün E; Magerl M; Graff J; Martinez-Saguer I; Kreuz W; Longhurst H; Nasr I; Bas M; Straßen U; Fang L; Cornpropst M; Dobo S; Collis P; Sheridan WP; Maurer M
    J Allergy Clin Immunol; 2016 Sep; 138(3):934-936.e5. PubMed ID: 27302552
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the safety and effectiveness of berotralstat for patients with hereditary angioedema: Report of six cases.
    Takamura S; Nakamura K; Fukuda T
    J Dermatol; 2023 Nov; 50(11):1506-1508. PubMed ID: 37721445
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary angioedema with normal C1 inhibitor.
    Bork K
    Immunol Allergy Clin North Am; 2013 Nov; 33(4):457-70. PubMed ID: 24176211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

  • 9. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
    Wu MA; Zanichelli A; Mansi M; Cicardi M
    Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary Angioedema.
    Busse PJ; Christiansen SC
    N Engl J Med; 2020 Mar; 382(12):1136-1148. PubMed ID: 32187470
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent advances in the management of hereditary angioedema.
    Hemperly SE; Agarwal NS; Xu YY; Zhi YX; Craig TJ
    J Am Osteopath Assoc; 2013 Jul; 113(7):546-55. PubMed ID: 23843378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of hereditary angioedema: When the goal is having a normal life.
    Arruda LK; Ferriani MPL
    J Allergy Clin Immunol; 2021 Jul; 148(1):80-82. PubMed ID: 34058236
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.
    Valerieva A; Staevska M; Jesenak M; Hrubiskova K; Sobotkova M; Zachova R; Hakl R; Andrejevic S; Suiter T; Grivcheva-Panovska V; Karadza-Lapic L; Soteres D; Shapiro R; Rumbyrt J; Tachdjian R; Mehta V; Hsu FI; Zanichelli A
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):799-802. PubMed ID: 31437566
    [No Abstract]   [Full Text] [Related]  

  • 16. Subcutaneous C1 Inhibitor for Long-term Prophylaxis of Hereditary Angioedema: A Real-life Experience.
    Baynova K; Cimbollek S; Quiralte J; García R; Lucena JM; Lasa Luaces E; Lara Jiménez MA; Alvarez Nieto J; Moreto J; González-Quevedo T
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):198-199. PubMed ID: 37796634
    [No Abstract]   [Full Text] [Related]  

  • 17. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous plasma-derived C1 inhibitor for long-term prophylaxis during pregnancy and breast-feeding in a patient with factor XII hereditary angioedema.
    Herraez L; Álvarez Sala P; Mielgo R
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2587-2588. PubMed ID: 37121510
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes.
    Joseph K; Bains S; Tholanikunnel BG; Bygum A; Aabom A; Koch C; Farkas H; Varga L; Ghebrehiwet B; Kaplan AP
    Allergy; 2015 Jan; 70(1):115-9. PubMed ID: 25186184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.
    Belbézier A; Boccon-Gibod I; Bouillet L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2490-2491. PubMed ID: 33556593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.